Biopharma Deal-Making In 2011: A Year Of Transition
Executive Summary
Approvals jumped, venture retrenched and dealmakers expanded on 2010’s creativity. Pharma’s thirst for payer-friendly innovation and emerging markets infrastructure pushed M&A valuations skyward, and threw VCs and drugmakers closer together. The year 2011 was also when we said goodbye to Lipitor, hello to the euro crisis, and “see you soon” to biosimilars.
You may also be interested in...
For Some VCs And Execs, Familiarity Breeds More Start-Ups
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.
For Some VCs And Execs, Familiarity Breeds More Start-Ups
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.